PPLPHARMA vs STAR: Stock Comparison

Piramal Pharma Limited vs Strides Pharma Science Limited

Live data: 27 July 2026, 4:08 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Piramal Pharma Limited shows a lower P/E, while Strides Pharma Science Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Piramal Pharma Limited and Strides Pharma Science Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, PPLPHARMA is more favourable on 1 of 13 scored metrics and STAR on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹25,562 Cr vs ₹9,624 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-78.29x vs 17.32x
P/B Ratio
STAR has a lower P/B
3.1x vs 3.12x
EPS
STAR has higher earnings per share
₹60.31 vs ₹-2.45
Dividend Yield
STAR has a higher dividend yield
0.37% vs 0.08%
Revenue Growth (TTM YoY)
STAR has faster revenue growth
11.2% vs -0.1%
EPS Growth (TTM YoY)
STAR has faster EPS growth
54.4% vs 0%
Qtr Sales Growth
STAR has stronger quarterly sales growth
11.2% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricPPLPHARMASTAR
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricPPLPHARMASTAR
Live Price₹192.05₹1,043
Day Change5.95%2.25%
Volume1.52 Cr2.49 L
52-Week High₹210.5₹1,231
52-Week Low₹132.3₹768.65
Distance from 52W High-8.76%-15.27%

Valuation

MetricPPLPHARMASTAR
Market Cap₹25,562 Cr₹9,624 Cr
P/E Ratio-78.29x17.32x
P/B Ratio3.12x3.1x
EPS₹-2.45₹60.31
Book Value₹64.78₹337.09
Dividend Yield0.08%0.37%

Growth

MetricPPLPHARMASTAR
Revenue Growth (TTM YoY)-0.1%11.2%
EPS Growth (TTM YoY)0%54.4%
Qtr Sales Growth-0.08%11.2%
Qtr Profit Growth-25%28.1%

Profitability & Leverage

MetricPPLPHARMASTAR
ROE-3.83%20.4%
ROCE2.52%18.6%
Net Margin-3.68%10.58%
Operating Margin10.4%19%
Debt to Equity0.7x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricPPLPHARMASTAR
Promoter Holding34.8% 0.06 pp27.91%
FII Holding12.52% 17.66 pp28.39% 0.29 pp
DII Holding14.57% 1.04 pp15.41% 0.96 pp
Public Holding37.63% 18.62 pp28.28% 0.67 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Piramal Pharma Limited and Strides Pharma Science Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.